Journal of the American Academy of Dermatology
Volume 60, Issue 1 , Pages 154-157, January 2009

Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin

  • Jayati Acharya, MRCP

      Affiliations

    • Department of Clinical Oncology, St James's Institute of Oncology, Leeds, United Kingdom
    • Corresponding Author InformationCorrespondence to: Jayati Acharya, MRCP, Department of Clinical Oncology, St James's Institute of Oncology, Beckett Street, Leeds, West Yorkshire, United Kingdom LS9 7TF.
  • ,
  • Calum Lyon, MA, FRCP

      Affiliations

    • Department of Dermatology, York District Hospital, York, United Kingdom
  • ,
  • David M. Bottomley, MRCP, FRCR

      Affiliations

    • Department of Clinical Oncology, St James's Institute of Oncology, Leeds, United Kingdom

Erlotinib, a specific epidermal growth factor receptor tyrosine kinase inhibitor, is used to treat various metastatic cancers. It is known to cause an acneiform rash. Herein, we report a case where the rash spared the previous radiotherapy field. A limitation of this study is that it is an anecdotal case report. Further research into the pathologic process of the rash is warranted to understand the reason for its absence in the irradiated skin.

 

 Funding sources: None.

 Conflicts of interest: None declared.

 Reprints not available from authors.

PII: S0190-9622(08)01015-3

doi:10.1016/j.jaad.2008.07.057

Journal of the American Academy of Dermatology
Volume 60, Issue 1 , Pages 154-157, January 2009